Revive Rx Can't End Eli Lilly's Suit Over Tirzepatide Drugs
A Texas federal judge has denied Revive Rx's bid to end Eli Lilly and Co.'s remaining unfair competition claims over the compounding pharmacy's sales of allegedly unapproved tirzepatide weight loss drugs...To view the full article, register now.
Already a subscriber? Click here to view full article